Shot In The Arm: U.S. FDA Approves Ranbaxy's Finished Dose Unit At Mohali; Company May Shore Up Product Filings
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA clears Ranbaxy's Punjab manufacturing site, clearing the Indian company to start shipping products to the U.S. again as Lipitor mystery continues.